

Zydus Cadila's Net Profit up by 114% in Q3

Ahmedabad, January 25, 2010

For the third quarter ended 31st December 2009, Cadila Healthcare Limited registered a Total Income of Rs. 993 crores up by 31% from Rs. 761 crores in the corresponding period last year, on a consolidated basis. The Net Profit after tax stood at Rs. 130 crores, up by 114% from Rs. 61 crores, during the same period last year.

During the quarter, the income growth was mainly driven by formulation exports which registered a growth of 45%. In the US, the company posted sales of Rs. 178 crores during the quarter, up by 67%. In Europe, the company registered sales of Rs. 104 crores during the quarter, up by 32%. Consumer wellness business grew by 42%, while API exports grew by 26%.

Coming back on the growth track, the India formulations business grew by healthy 17%. The group launched 24 new products including line extensions in the domestic market. Of these, 10 were the first in India launches.

During the quarter, the group acquired the balance 30% shares in Simayla Pharmaceuticals, making it a 100% subsidiary in South Africa.

The group recently commenced the clinical trials of H1N1 vaccine and is likely to launch the product after successful completion of trials in April 2010.

This quarter, the group filed 4 more ANDAs and 3 additional US DMFs, taking the total to 99 ANDA filings and 85 US DMFs. The group has received 52 product approvals so far for US market.

###